Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4564249
Max Phase: Preclinical
Molecular Formula: C85H123N13O30S
Molecular Weight: 1839.05
Molecule Type: Unknown
Associated Items:
ID: ALA4564249
Max Phase: Preclinical
Molecular Formula: C85H123N13O30S
Molecular Weight: 1839.05
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@H](NC(=O)[C@H](Cc1ccc(OS(=O)(=O)O)cc1)NC(=O)[C@H](CC(=O)O)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)O)C(=O)NCC(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(N)=O
Standard InChI: InChI=1S/C85H123N13O30S/c1-2-3-26-61(79(113)90-52-71(101)92-66(48-57-51-89-60-27-22-21-25-59(57)60)82(116)95-62(35-37-75(106)107)80(114)98-68(50-77(110)111)84(118)96-64(78(86)112)46-55-23-17-16-18-24-55)94-81(115)65(47-56-30-32-58(33-31-56)128-129(121,122)123)97-83(117)67(49-76(108)109)93-73(103)54-127-45-43-125-41-39-88-72(102)53-126-44-42-124-40-38-87-69(99)36-34-63(85(119)120)91-70(100)28-19-14-12-10-8-6-4-5-7-9-11-13-15-20-29-74(104)105/h16-18,21-25,27,30-33,51,61-68,89H,2-15,19-20,26,28-29,34-50,52-54H2,1H3,(H2,86,112)(H,87,99)(H,88,102)(H,90,113)(H,91,100)(H,92,101)(H,93,103)(H,94,115)(H,95,116)(H,96,118)(H,97,117)(H,98,114)(H,104,105)(H,106,107)(H,108,109)(H,110,111)(H,119,120)(H,121,122,123)/t61-,62-,63-,64-,65-,66-,67-,68-/m0/s1
Standard InChI Key: ITJOYTQXPBFWJA-PZENOAITSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1839.05 | Molecular Weight (Monoisotopic): 1837.8220 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Sensfuss U, Kruse T, Skyggebjerg RB, Uldam HK, Vestergaard B, Huus K, Vinther TN, Reinau ME, Schéele S, Clausen TR.. (2019) Structure-Activity Relationships and Characterization of Highly Selective, Long-Acting, Peptide-Based Cholecystokinin 1 Receptor Agonists., 62 (3): [PMID:30624060] [10.1021/acs.jmedchem.8b01558] |
Source(1):